#36: Talc About Trouble: J&J Hit with $966M Verdict

• 💓 Abbott unveils world’s first dual-chamber leadless pacemaker in India, where two tiny devices sync wirelessly for a natural heartbeat. (BioS)

• 🫄Choice and SilMach introduced a rice-sized wireless implant that opens or closes your fallopian tubes on demand. A hormone-free “on/off” switch for fertility. (techeu)

• 🎓 Microsoft struck a licensing deal with Harvard Medical School, getting access to its consumer health, part of a bold move to enhance its Copilot AI assistant. (Reuters)

• 🧪 India’s taking the TB fight to the bloodstream with a new local test that spots TB faster and cheaper. (ETHealthWorld)

• 🍞 Tumours, consider yourselves toast! A new precision ultrasound technique destroys cancer tumours in hours without surgery, leaving healthy tissue untouched. (BBC)

•  🦟India’s buzzing with pride as it unveils Renofluthrin, a new mosquito-repellent offering safer, longer-lasting protection against dengue, malaria, and chikungunya. (PharmaBiz)

• 😴 Tired of being told it’s all in your head? A new blood test could finally give chronic fatigue patients clear answers. (TheGuardian)

• ⚖️ Baby Powder Fallout: J&J faces $966M verdict for baby powder linked to cancer in one case amid 70,000+ ongoing claims. (Bloomberg)

• 💵 Indian pharma pops a happy pill as Trump halts generic drug tariffs. (ET)

• 💊 Pick up your meds on the go! Amazon turns vending machines into instant prescription dispensers at One Medical clinics. (TheVerge)

• 🤖 Slow and steady no more! UK clinical trial approvals now take 41 days versus 91. However could faster approvals bring new challenges for safety oversight? (PharmaBiz)

🇮🇳 India

• ❌ Cough Syrup Panic Deepens: Over 21 child deaths prompt statewide bans on multiple syrups. Sresan Pharma owner arrested, prescribing doctor detained, and major lapses in testing uncovered. (ETHealthWorld) (ETHealthWorld)

• 🏥 More ka-ching for every stitch! Super-specialty hospitals receive higher reimbursements for procedures under revised Central Government Health Scheme rates. (BS)

• 🚨 Critical care failure? Right To Information (RTI) plea reveals that one-third of ventilators are defunct in Delhi's major government hospitals, CM denies report. (MD)

🌏️ Global

• ⚠️ Cyber Alert: With cybersecurity laws expired and a Washington shutdown in play, US hospitals face higher risks of data breaches, putting patient data in danger. (HealthcareIT)

🇮🇳 India

• 💸 Eli Lilly invests $1B in India! New hubs will make key medicines, including Mounjaro— now India’s second highest-selling drug, behind GSK’s Augmentin. (Reuters) (TOI)

• 📰 International Healthcare Holdings’ takeover of Fortis gets SEBI approval, sending Fortis shares up ~6.7% and reviving a deal stalled since 2018. (VCCircle)

• 🏗️ National Stock Exchange (NSE) to fund a ₹380 Cr, 60-bed cancer unit for Tata Memorial Centre. (ETHealthWorld)

• 🔥 Rubicon Research IPO sizzles in pre-launch trading, ₹1,377 Cr buzz in grey market. (ET)

• 👁️ ASG Eye Hospitals joins forces with Sharp Sight in ₹450 Cr mega deal ahead of IPO. (ET)

🌏️ Global

• 🇺🇸 Made in the USA: Drug giant AstraZeneca breaks ground on $4.5B manufacturing site responding to U.S. political pressure. (Reuters)

• 💰 $2B Bet: Zenas Bio secures global rights to Chinese autoimmune drug, Orelabrutinib. (Reuters)

📢 Enjoyed this edition? Forward it to a friend or colleague who’d love to stay informed! They can subscribe here.